Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone631-924-1135
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$33.41 million
Profitability
Miscellaneous
Employees295
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions
What is Chembio Diagnostics' stock symbol?
Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."
How were Chembio Diagnostics' earnings last quarter?
Chembio Diagnostics Inc (NASDAQ:CEMI) released its quarterly earnings data on Wednesday, May, 1st. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The business had revenue of $8.30 million for the quarter, compared to analysts' expectations of $8.24 million. Chembio Diagnostics had a negative return on equity of 36.34% and a negative net margin of 29.51%. View Chembio Diagnostics' Earnings History.
When is Chembio Diagnostics' next earnings date?
What guidance has Chembio Diagnostics issued on next quarter's earnings?
Chembio Diagnostics updated its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $36-40 million, compared to the consensus revenue estimate of $40.39 million.
What price target have analysts set for CEMI?
3 analysts have issued 1 year price targets for Chembio Diagnostics' stock. Their predictions range from $10.00 to $14.00. On average, they anticipate Chembio Diagnostics' stock price to reach $12.00 in the next year. This suggests a possible upside of 55.8% from the stock's current price. View Analyst Price Targets for Chembio Diagnostics.
What is the consensus analysts' recommendation for Chembio Diagnostics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chembio Diagnostics.
Has Chembio Diagnostics been receiving favorable news coverage?
News headlines about CEMI stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chembio Diagnostics earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Chembio Diagnostics' key competitors?
Some companies that are related to Chembio Diagnostics include Akorn (AKRX), Urogen Pharma (URGN), Revance Therapeutics (RVNC), Basilea Pharmaceutica (BPMUF), Synthorx (THOR), CytomX Therapeutics (CTMX), Flexion Therapeutics (FLXN), NuCana (NCNA), BioSpecifics Technologies (BSTC), Corium International (CORI), Corbus Pharmaceuticals (CRBP), ProQR Therapeutics (PRQR), Evolus (EOLS), Albireo Pharma (ALBO) and Vital Therapies (VTL).
What other stocks do shareholders of Chembio Diagnostics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Novocure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and Rewalk Robotics (RWLK).
Who are Chembio Diagnostics' key executives?
Chembio Diagnostics' management team includes the folowing people:
- Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
- Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
- Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
- Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
- Mr. David A. Gyorke, Sr. VP & COO (Age 59)
Who are Chembio Diagnostics' major shareholders?
Chembio Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional investors include ARS Investment Partners LLC (2.92%), Wells Fargo & Company MN (1.81%), Gagnon Securities LLC (1.76%), Ingalls & Snyder LLC (1.75%), Perkins Capital Management Inc. (1.59%) and Penbrook Management LLC (0.74%). Company insiders that own Chembio Diagnostics stock include John Gary Potthoff, Neil A Goldman, Norman H Pessin and Robert Passas. View Institutional Ownership Trends for Chembio Diagnostics.
Which major investors are selling Chembio Diagnostics stock?
CEMI stock was sold by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC, Ingalls & Snyder LLC, Renaissance Technologies LLC, Northern Trust Corp and Gagnon Securities LLC. View Insider Buying and Selling for Chembio Diagnostics.
Which major investors are buying Chembio Diagnostics stock?
CEMI stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Penbrook Management LLC, Wells Fargo & Company MN, Marshall Wace North America L.P., Spark Investment Management LLC and Morgan Stanley. Company insiders that have bought Chembio Diagnostics stock in the last two years include John Gary Potthoff, Neil A Goldman, Norman H Pessin and Robert Passas. View Insider Buying and Selling for Chembio Diagnostics.
How do I buy shares of Chembio Diagnostics?
Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chembio Diagnostics' stock price today?
One share of CEMI stock can currently be purchased for approximately $7.70.
How big of a company is Chembio Diagnostics?
Chembio Diagnostics has a market capitalization of $132.21 million and generates $33.41 million in revenue each year. The company earns $-7,870,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Chembio Diagnostics employs 295 workers across the globe.
What is Chembio Diagnostics' official website?
How can I contact Chembio Diagnostics?
Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]
MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
